Gaudium IVF & Women Health Quarterly Results for Trading Insights
In Sept 2025, Gaudium IVF & Women Health (GAUDIUMIVF) reported revenue ₹32 Cr and net profit ₹9 Cr. Compare with GAUDIUMIVF fundamental valuation to assess whether the stock is under or overvalued.
GAUDIUMIVF Quarterly Results — Revenue, Profit & EPS Highlights
Gaudium IVF & Women Health latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. For annual financials, live price and key ratios, visit Gaudium IVF & Women Health share price today.
- Revenue of ₹32 Cr in Sept 2025 (+18.5% vs Mar 2025)
- Net Profit of ₹9 Cr in Sept 2025 (+28.6% vs Mar 2025)
- EBITDA of ₹14 Cr in Sept 2025 (+55.6% vs Mar 2025)
- Operating Margin of 43.0% in Sept 2025 (+10.0pp vs Mar 2025)
- Earnings Per Share of ₹1.53 in Sept 2025 (+43.0% vs Mar 2025)
Gaudium IVF & Women Health Quarterly Results — Revenue, EBITDA, Net Profit & EPS
GAUDIUMIVF quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Sept 2025 | Mar 2025 | Jun 2025 | Dec 2025 | Dec 2024 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 32 | 27 | 18 | 25 | 14 | 18.5% | - |
| Net Profit (₹ Cr) | 9 | 7 | 3 | 4 | 3 | - | - |
| EBITDA (₹ Cr) | 14 | 9 | 5 | 7 | 6 | - | - |
| EPS (₹) | 1.53 | 1.07 | 0.51 | 0.59 | 0.55 | - | - |
| Operating Margin (%) | 43.0% | 33.0% | 29.0% | 27.0% | 39.0% | - | - |
GAUDIUMIVF Share Price Trend — 1-Year Movement Across Quarterly Results
Gaudium IVF & Women Health 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Also explore GAUDIUMIVF price movement history to track price trends across different timeframes.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
GAUDIUMIVF vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Gaudium IVF & Women Health latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹442,581.33 Cr | 1840.6 | 15,018 | 2,710 | +1.0% | +11.8% | 18.0% | 162.9 |
|
Divis Laboratories
Sept 2025 |
₹179,470.03 Cr | 6756.5 | 2,860 | 689 | +7.1% | - | 24.1% | 260.2 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹151,833.39 Cr | 4572.6 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 397.3 |
|
Cipla
Mar 2026 |
₹113,024.67 Cr | 1413.9 | 6,612 | 543 | -14.3% | -4.0% | 8.2% | 205.8 |
|
Dr Reddys Laborator…
Mar 2026 |
₹109,104.54 Cr | 1331.4 | 7,996 | 221 | -12.5% | -11.5% | 2.8% | 502.4 |
All amounts in ₹ Crores